Remove DNA Remove Laboratories Remove Protein Production
article thumbnail

Proteogenomics reveals markers of chemotherapy resistance and outcome in triple negative breast cancer

Broad Institute

Data from standard DNA and RNA sequencing approaches were integrated with mass spectrometry-based proteomics and phosphoproteomic analyses to derive more complete molecular portraits of treatment-responsive versus treatment-resistant tumors. "The These data suggest a multi-omics predictor for chemotherapy response is within reach.

DNA 52
article thumbnail

Global advances in synthetic biology

Drug Discovery World

It is believed that the term synthetic biology was created in 1970 by geneticist, Waclaw Szybalski 1 as work was being carried out on the development of DNA sequencing and synthesis techniques. These factors can significantly contribute to the growth of the synthetic biology market, it adds. . Brady and colleagues turned to algorithms.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Merkin Prize in Biomedical Technology awarded to F. William Studier for development of widely used protein- and RNA-production platform

Broad Institute

William Studier for development of widely used protein- and RNA-production platform The $400,000 award recognizes the far-reaching medical impacts of Studier’s development, in the 1980s, of an efficient and scalable technology to produce mass amounts of RNA and proteins in laboratories that is widely used today all over the world.

RNA 84
article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’. They will present on expression and characterisation of novel GCN-related N-acetyltransferases by Nucleras rapid protein assess system.

article thumbnail

Article FDA Thank You Draft guidance on potency assays for CGT products garners extensive stakeholder input

Agency IQ

BY RACHEL COE, MSC | APR 11, 2024 1:06 PM CDT Regulatory background: Product potency and assays As defined in statute , the FDA uses the term “potency” to refer to the “specific ability or capability” of a product to “effect a given result.” morphological cell changes or alterations in protein production or expression).

article thumbnail

The inner workings of antibiotics

Drug Discovery World

Others, like tetracycline and aminoglycosides, inhibit the function of ribosomes, the cellular machinery responsible for protein production. Additionally, drugs like quinolones and rifampin disrupt the synthesis of nucleic acids, which are essential for bacterial DNA replication.

article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

Next-generation immunotherapies In the session focused on cell-based immunotherapies, Steven Quistad, Senior Applications Scientist, DNA Script, presented on how to rapidly assemble genes in a laboratory using automated enzymatic oligo synthesis. To demonstrate the utility of the company’s SYNTAX system in gene assembly, the 1.7